BACKGROUND: Adequate zinc is critical for immune function; however, zinc deficiency occurs in >50% of human immunodeficiency virus (HIV)-infected adults. We examined the safety and efficacy of long-term zinc supplementation in relation to HIV disease progression. METHODS: A prospective, randomized, controlled clinical trial was conducted involving 231 HIV-infected adults with low plasma zinc levels (<0.75 mg/L), who were randomly assigned to receive zinc (12 mg of elemental zinc for women and 15 mg for men) or placebo for 18 months. The primary end point was immunological failure. HIV viral load and CD4(+) cell count were determined every 6 months. Questionnaires, pill counts, and plasma zinc and C-reactive protein levels were used to monitor adherence to study supplements and antiretroviral therapy. Intent-to-treat analysis used multiple-event analysis, treating CD4(+) cell count <200 cells/mm(3) as a recurrent immunological failure event. Cox proportional hazard models and the general-linear model were used to analyze morbidity and mortality data. RESULTS:Zinc supplementation for 18 months reduced 4-fold the likelihood of immunological failure, controlling for age, sex, food insecurity, baseline CD4(+) cell count, viral load, and antiretroviral therapy (relative rate, 0.24; 95% confidence interval, 0.10-0.56; P<.002). Viral load indicated poor control with antiretroviral therapy but was not affected by zinc supplementation. Zinc supplementation also reduced the rate of diarrhea by more than half (odds ratio, 0.4; 95% confidence interval, 0.183-0.981; P=.019), compared with placebo. There was no significant difference in mortality between the 2 groups. CONCLUSIONS: This study demonstrated that long-term (18-month) zinc supplementation at nutritional levels delayed immunological failure and decreased diarrhea over time. This evidence supports the use of zinc supplementation as an adjunct therapy for HIV-infected adult cohorts with poor viral control. Trial registration. ClinicalTrials.gov identifier: NCT00149552.
RCT Entities:
BACKGROUND: Adequate zinc is critical for immune function; however, zinc deficiency occurs in >50% of humanimmunodeficiency virus (HIV)-infected adults. We examined the safety and efficacy of long-term zinc supplementation in relation to HIV disease progression. METHODS: A prospective, randomized, controlled clinical trial was conducted involving 231 HIV-infected adults with low plasma zinc levels (<0.75 mg/L), who were randomly assigned to receive zinc (12 mg of elemental zinc for women and 15 mg for men) or placebo for 18 months. The primary end point was immunological failure. HIV viral load and CD4(+) cell count were determined every 6 months. Questionnaires, pill counts, and plasma zinc and C-reactive protein levels were used to monitor adherence to study supplements and antiretroviral therapy. Intent-to-treat analysis used multiple-event analysis, treating CD4(+) cell count <200 cells/mm(3) as a recurrent immunological failure event. Cox proportional hazard models and the general-linear model were used to analyze morbidity and mortality data. RESULTS: Zinc supplementation for 18 months reduced 4-fold the likelihood of immunological failure, controlling for age, sex, food insecurity, baseline CD4(+) cell count, viral load, and antiretroviral therapy (relative rate, 0.24; 95% confidence interval, 0.10-0.56; P<.002). Viral load indicated poor control with antiretroviral therapy but was not affected by zinc supplementation. Zinc supplementation also reduced the rate of diarrhea by more than half (odds ratio, 0.4; 95% confidence interval, 0.183-0.981; P=.019), compared with placebo. There was no significant difference in mortality between the 2 groups. CONCLUSIONS: This study demonstrated that long-term (18-month) zinc supplementation at nutritional levels delayed immunological failure and decreased diarrhea over time. This evidence supports the use of zinc supplementation as an adjunct therapy for HIV-infected adult cohorts with poor viral control. Trial registration. ClinicalTrials.gov identifier: NCT00149552.
Authors: C J Bates; P H Evans; M Dardenne; A Prentice; P G Lunn; C A Northrop-Clewes; S Hoare; T J Cole; S J Horan; S C Longman Journal: Br J Nutr Date: 1993-01 Impact factor: 3.718
Authors: N M Graham; D Sorensen; N Odaka; R Brookmeyer; D Chan; W C Willett; J S Morris; A J Saah Journal: J Acquir Immune Defic Syndr (1988) Date: 1991
Authors: R S Beach; E Mantero-Atienza; G Shor-Posner; J J Javier; J Szapocznik; R Morgan; H E Sauberlich; P E Cornwell; C Eisdorfer; M K Baum Journal: AIDS Date: 1992-07 Impact factor: 4.177
Authors: Ajibola I Abioye; Sheila Isanaka; Enju Liu; Ramadhani S Mwiru; Ramadhani A Noor; Donna Spiegelman; Ferdinand Mugusi; Wafaie Fawzi Journal: AIDS Care Date: 2015-01-06
Authors: Natalia Gnatienko; Matthew S Freiberg; Elena Blokhina; Tatiana Yaroslavtseva; Carly Bridden; Debbie M Cheng; Christine E Chaisson; Dmitry Lioznov; Sally Bendiks; Glory Koerbel; Sharon M Coleman; Evgeny Krupitsky; Jeffrey H Samet Journal: HIV Clin Trials Date: 2018-04-17